Table 5.

Financial benefits (in €) associated with vaccination of previously vaccinated sows (preVS), when vaccination effectiveness of a potential new vaccine (nVac) is +10% compared to the previously used alternative vaccine.

Proportion of nVac in preVS	Vaccination coverage
	40%	50%	60%	70%	80%
10%	2′287′440	2′859′300	3′431′160	4′003′020	4′574′880
20%	4′574′880	5′718′600	6′862′320	8′006′040	9′149′760
30%	6′862′320	8′577′900	10′293′480	12′009′060	13′724′640
40%	9′149′760	11′437′200	13′724′640	16′012′080	18′299′520
50%	11′437′200	14′296′500	17′155′800	20′015′100	22′874′400
60%	13′724′640	17′155′800	20′586′960	24′018′120	27′449′280
70%	16′012′080	20′015′100	24′018′120	28′021′140	32′024′160
80%	18′299′520	22′874′400	27′449′280	32′024′160	36′599′040
90%	20′586′960	25′733′700	30′880′440	36′027′180	41′173′920
100%	22′874′400	28′593′000	34′311′600	40′030′200	45′748′800

Estimates depend on vaccination coverage and the proportion of preVS that are newly vaccinated with nVac.